Journal of Asthma and Allergy (Dec 2021)
Demographics, Treatment Patterns, and Morbidity in Patients with Exercise-Induced Bronchoconstriction: An Administrative Claims Data Analysis
Abstract
Miguel J Lanz,1 Ileen A Gilbert,2 Hitesh N Gandhi,2 Nadia Goshi,3 Joseph P Tkacz,4 Njira L Lugogo5 1Allergy and Asthma, AAADRS Clinical Research Center, Coral Gables, FL, USA; 2BioPharmaceuticals Medical – US, AstraZeneca, Wilmington, DE, USA; 3BioPharmaceuticals Global Medicines Development – US, AstraZeneca, Wilmington, DE, USA; 4IBM Watson Health, Cambridge, MA, USA; 5Pulmonary Clinic, Michigan Medicine, University of Michigan, Ann Arbor, MI, USACorrespondence: Ileen A GilbertBioPharmaceuticals Global Medicines Development – US, AstraZeneca, 1800 Concord Pike, Wilmington, DE, 19803, USATel +1 262-227-0686Email [email protected]: Exercise-induced bronchoconstriction (EIB) is generally treated with short-acting β2-agonists (SABA) before exercising, to prevent symptoms. Real-world data on treatments and outcomes for patients with EIB alone (EIBalone), or with asthma (EIBasthma), in the USA are limited. This study compared demographics, treatment patterns, morbidity, and costs of treating EIB between these two groups of patients.Patients and Methods: Administrative claims from US IBM® MarketScan® Research databases were analyzed retrospectively. Patients aged ≥ 4 years filling a SABA claim between 1/1/2011 and 12/31/2016 were evaluated. Patients were indexed on a random SABA claim and required to have 12 months’ continuous eligibility pre- and post-index, ≥ 1 maintenance medication and/or SABA fill post-index, and were designated EIBalone or EIBasthma according to diagnostic codes (EIB only or EIB plus asthma, respectively). Descriptive statistics were used.Results: In total, 13,480 patients had EIBalone and 14,862 had EIBasthma. Compared with EIBasthma, the EIBalone group was older (mean[SD] 20.4[13.6] vs 17.8[13.6] years), had more females (60.7% vs 54.7%), and filled fewer SABA claims (1.9[1.4] vs 2.5[2.2]) (all p< 0.001). A smaller proportion of patients in the EIBalone than EIBasthma group had maintenance therapy claims (79.9% vs 90.6%, p< 0.001). The EIBalone group also had a lower proportion of patients with oral or injectable corticosteroid claims (29.4% vs 32.0%) and asthma and/or EIB-related emergency department (1.0% vs 13.0%) or outpatient visits (65.1% vs 72.3%; all p< 0.0001). Annual days’ supply of oral corticosteroids was similar between groups (mean[SD] EIBalone: 20.7[30.8] vs EIBasthma: 19.8[28] days).Conclusion: Individuals with EIBalone or EIBasthma demonstrate considerable morbidity. New treatment paradigms may be needed to optimize outcomes for both patient groups.Keywords: asthma, drug prescriptions, healthcare costs, short-acting beta2-agonist
